Volitionrx Ltd (NYSE:VNRX) recently announced the initiation of a two-phase logistical study for its Nu.Q™ Triage test for colorectal cancer (CRC) in Denmark, which may enable the inclusion of the test in the country’s national screening program in conjunction with the standard fecal immunochemical test (FIT). The study is expected to take six months to complete with the potential for a decision by the national screening committee by the end of the year. If included, the Nu.Q™ Triage test would be the first blood-based cancer diagnostic as part of a national screening program for CRC.
Unnecessary colonoscopies mar screening programs
Current screening methodologies, such as the FIT test, lead to a large number of false positives. According to data from national screening programs that use FIT, there are around 20 false positives for every true positive, leading to a large number of unnecessary colonoscopies, which tax the health system.
To read the entire report Please click on the pdf File Below